Skip to main content

Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA

A Correction to this article was published on 13 February 2020

This article has been updated

Abstract

Purpose

The purpose of this study was to perform a prospective integrated analysis of 18F-fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) and circulating tumor DNA (ctDNA) to assess responses to multimodal chemotherapy in children and adolescents suffering from Ewing sarcoma (EwS).

Methods

A total of 20 patients with histologically confirmed EwS underwent multiple 18F-FDG-PET/CT, performed at the time of each patient’s initial diagnosis and after the second and fifth induction chemotherapy block (EWING2008 treatment protocol, NCT00987636). Additional PET examinations were performed as clinically indicated in some patients, e.g., in patients suspected of having progressive or relapsing disease. All 263 18F-FDG-positive lesions in the field of view suggestive of tumor tissue were assessed quantitatively to calculate PET-derived parameters, including whole-body metabolic tumor volume (wb-MTV) and whole-body total lesion glycolysis (wb-TLG), as well as the following data: standardized uptake value (SUV)max and SUVmean. Tumor-specific ctDNA in patient plasma samples was quantified using digital droplet PCR (ddPCR), and the correlations between ctDNA levels and PET-derived parameters were analyzed. Metabolic responses to multimodal chemotherapy as assessed with PET-parameters were compared to biochemical responses as assessed with changes in ctDNA levels.

Results

Twenty patients underwent a total of 87 18F-FDG-PET/CT scans, which detected 263 FDG-positive tumor lesions. Significant correlations between SUVmax, SUVmean, wb-MTV and wb-TLG values, and ctDNA levels were observed (all p < 0.0001). All patients suffering from EwS, with histology serving as gold standard, also presented with a positive corresponding ctDNA sample and a positive 18F-FDG-PET/CT examination before initiation of therapy. There were no false-negative results. Evaluation of treatment response after the fifth block of induction chemotherapy showed that the agreement between the metabolic response and biochemical response was 90%, which was statistically significant (Cohen κ = 0.62; p < 0.05). Non-detectable ctDNA after the second block of induction chemotherapy was associated with complete biochemical and metabolic responses after the fifth block of induction chemotherapy in 16/17 patients (94%). During a median follow-up period of 36 months (range: 8–104 months), four patients had tumor relapses, which, in all cases, were accompanied by an increase in plasma ctDNA levels and a positive 18F-FDG-PET/CT. No false-negative results were observed in the study cohort. Complete biochemical and metabolic responses after the fifth block of induction chemotherapy had a high positive predictive value for disease remission during the follow-up period; specifically, the positive predictive value was 88%.

Conclusion

The combination of 18F-FDG-PET/CT and ctDNA quantification is a very promising noninvasive tool for assessing treatment responses and detecting tumor relapses in children and young adolescents suffering from EwS who are undergoing multimodal chemotherapy.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Change history

  • 13 February 2020

    The author names and family names of the originally published article was inversed. Correct presentation is presented here.

References

  1. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol. 2008;20(4):412–8.

    PubMed  Article  Google Scholar 

  2. Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, et al. Survival after recurrence of Ewing tumors: the St. Jude children's research hospital experience, 1979–1999. Cancer. 2002;94(2):561–9.

    PubMed  Article  Google Scholar 

  3. Pappo AS, Dirksen U. Rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas. J Clin Oncol. 2017;36(2):168–79.

    PubMed  Article  Google Scholar 

  4. Grünewald TG, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, et al. Ewing sarcoma (Primer). Nat Rev Dis Primers. 2018;4(1):5.

    PubMed  Article  Google Scholar 

  5. Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284–91.

    CAS  PubMed  Article  Google Scholar 

  6. Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;57(4):549–53.

    PubMed  Article  Google Scholar 

  7. Bosma S, Lancia C, Rueten-Budde A, Ranft A, Gelderblom H, Fiocco M, et al. Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. Sci Rep. 2019;9(1):11000.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley M-C, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–46.

    CAS  PubMed  Article  Google Scholar 

  9. Pan G, Raymond A, Carrasco C, Wallace S, Kim E, Shirkhoda A, et al. Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology. 1990;174(2):517–26.

    CAS  PubMed  Article  Google Scholar 

  10. Holscher HC, Bloem J, Nooy M, Taminiau A, Eulderink F, Hermans J. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR Am J Roentgenol. 1990;154(4):763–9.

    CAS  PubMed  Article  Google Scholar 

  11. Denecke T, Hundsdörfer P, Misch D, Steffen IG, Schönberger S, Furth C, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging. 2010;37(10):1842–53.

    PubMed  Article  Google Scholar 

  12. Gobel V, Jurgens H, Etspuler G, Kemperdick H, Jungblut RM, Stienen U, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113(2):187–91.

    CAS  PubMed  Article  Google Scholar 

  13. Hense HW, Ahrens S, Paulussen M, Lehnert M, Jurgens H. Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies. Ann Oncol. 1999;10(9):1073–7.

    CAS  PubMed  Article  Google Scholar 

  14. Kasalak O, Overbosch J, Glaudemans A, Boellaard R, Jutte PC, Kwee TC. Primary tumor volume measurements in Ewing sarcoma: MRI inter- and intraobserver variability and comparison with FDG-PET. Acta Oncol. 2018;57(4):534–40.

    CAS  PubMed  Article  Google Scholar 

  15. Erlemann R, Sciuk J, Bosse A, Ritter J, Kusnierz-Glaz CR, Peters PE, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175(3):791–6.

    CAS  PubMed  Article  Google Scholar 

  16. Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol. 1991;157(4):825–33.

    CAS  PubMed  Article  Google Scholar 

  17. Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol. 2017;178(5):709–18.

    CAS  PubMed  Article  Google Scholar 

  18. Usmanij EA, Natroshvili T, Timmer-Bonte JNH, Oyen WJG, van der Drift MA, Bussink J, et al. The predictive value of early in-treatment 18F-FDG PET/CT response to chemotherapy in combination with bevacizumab in advanced nonsquamous non–small cell lung cancer. J Nucl Med. 2017;58(8):1243–8.

    CAS  PubMed  Article  Google Scholar 

  19. Avril S, Muzic RF, Plecha D, Traughber BJ, Vinayak S, Avril N. 18F-FDG PET/CT for monitoring of treatment response in breast Cancer. J Nucl Med. 2016;57(Suppl 1):34S–9S.

    CAS  PubMed  Article  Google Scholar 

  20. Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJJ, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000;27(6):731–43.

    CAS  PubMed  Article  Google Scholar 

  21. Frings V, Velden FHPv, Velasquez LM, Hayes W, Ven PMvd, Hoekstra OS, et al. Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 2014;273(2):539–548.

  22. Franzius C, Sciuk J, Brinkschmidt C, JÜRGENS H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25(11):874–81.

    CAS  PubMed  Article  Google Scholar 

  23. Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB III, EUC, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23(34):8828–34.

    PubMed  Article  Google Scholar 

  24. van Rossum PS, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, et al. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2017;44(1):71–80.

    PubMed  Article  Google Scholar 

  25. Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. Bäuerle T, Semmler W. Imaging response to systemic therapy for bone metastases. Eur Radiol. 2009;19(10):2495–507.

    PubMed  Article  Google Scholar 

  27. Elzi DJ, Song M, Houghton PJ, Chen Y, Shiio Y. The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma. Genes Cancer. 2015;6(11–12):452.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 2010;29(32):4504.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, Nycum L, et al. EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest. 1994;94(2):489–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. Krumbholz M, Hellberg J, Steif B, Bäuerle T, Gillmann C, Fritscher T, et al. Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in Ewing sarcoma. Clin Cancer Res. 2016;22(17):4356–65.

    CAS  PubMed  Article  Google Scholar 

  31. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50(3):340–7.

    PubMed  Article  Google Scholar 

  32. Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, et al. The value of 18 F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging. 2014;41(9):1756–66.

    CAS  PubMed  Article  Google Scholar 

  33. Berger M, Dirksen U, Braeuninger A, Koehler G, Juergens H, Krumbholz M, et al. Genomic EWS-FLI1 fusion sequences in Ewing sarcoma resemble breakpoint characteristics of immature lymphoid malignancies. PLoS One. 2013;8(2):e56408.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. Joo Hyun O, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576.

    Article  Google Scholar 

  35. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37–46.

    Article  Google Scholar 

  36. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977:159–74.

  37. Rasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014;61(8):1382–6.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Sabine Semper for providing excellent technical assistance.

Funding

This work was funded by the Interdisziplinäres Zentrum für Klinsiche Forschung (IZKF) of Friedrich-Alexander University Erlangen-Nürnberg (FAU) (grant to CS), the Barbara und Hubertus Trettner Stiftung, project number T0355/31554/2018/sm (grant to UD and MM) and a research grant from “Schornsteinfeger helfen krebskranken Kindern,” Germany (grant to MK and MM). The German Cancer Aid grant 108128 to UD. ERA-Net-TRANSCAN consortium, project number 01KT1310 to UD, and Euro Ewing Consortium EEC, project number EU-FP7 602856 to UD and MM), both funded under the European Commission Seventh Framework Program FP7-HEALTH (http://cordis.europa.eu/) (to UD).

Author information

Authors and Affiliations

Authors

Contributions

Designed the study: Schmidkonz C, Krumbholz M, and Metzler M

Acquired the data: Schmidkonz C, Krumbholz M, Metzler M, Cordes M, Atzinger A, and Dirksen U

Analyzed/interpreted the data: Schmidkonz C, Krumbholz M, Metzler M, Cordes M, Bäuerle T, Goetz Th I, Ritt P, and Kuwert T

Contributed reagents/materials/analysis tools: Schmidkonz C, Krumbholz M, Prante O, Metzler M, Agaimy A, Hartmann W, Rössig C, Fröhlich B, Dirksen U, Schaefer C, and Goetz Th I

Drafted the manuscript: Schmidkonz C, Krumbholz M, Metzler M, and Kuwert T

Revised the manuscript: Schmidkonz C, Krumbholz M, Metzler M, Kuwert T, Cordes M, Prante O, Bäuerle T, Ritt P, Atzinger A, Goetz Th I, Rössig C, Fröhlich B, and Dirksen U

Corresponding author

Correspondence to Christian Schmidkonz.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individuals who participated in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised due to author names and family names being inversed.

This article is part of the Topical Collection on Oncology – Muskoskeletal

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schmidkonz, C., Krumbholz, M., Atzinger, A. et al. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA. Eur J Nucl Med Mol Imaging 47, 1564–1575 (2020). https://doi.org/10.1007/s00259-019-04649-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04649-1

Keywords

  • Pediatric oncology
  • Ewing sarcoma
  • Circulating tumor DNA
  • 18F-FDG PET/CT
  • Treatment response